Maurizio Scarpa, MD, PhD, pediatrician, is the Director of the Rare Disease Program at the Regional IRCCS San Gerardo dei Tintori Research Hospital in Monza, Italy. He is Professor of Pediatrics at the Dept. for the Woman and Child Health, University of Padova, Italy, and the Co-Founder of the Brains For Brain Foundation, together with the late Prof. David Begley, King’s College London, London, UK. Prof. Scarpa has extensive expertise as a basic scientist in genetics and biotechnology, as well as a clinician in the diagnosis and treatment of paediatric rare disorders; neurometabolic diseases in particular. Together with dr. Christina Lampe he founded the Center for Rare Diseases at the Helios Dr. Horst Schmidt Kliniken in Wiesbaden, Germany. He is especially interested in developing innovative health approaches for the diagnosis and the treatment of metabolic inherited diseases; to this aim he is also collaborating with major biotech companies as an external independent expert. Prof. Scarpa is the Coordinator of the European Reference Network for Hereditary Metabolic Diseases, MetabERN, formed by 101 healthcare providers in 27 EU countries (www.metab.ern-net.eu ) to facilitate patient-centered holistic activities to implement knowledge, diagnosis, management and treatment for inherited metabolic diseases.
Moving beyond isolated advocacy to accelerate diagnosis, this workshop will holistically explore how early diagnosis fits within the rare disease ecosystem from development of diagnostic technologies, to care pathways and policy frameworks. It will be based on a three-part discussion to:
- Move beyond purely technical debates
- Elicit a range of opinions and different practices
- Align with European policy developments in rare diseases.
- Patient led solutions to orphan drug development and access bottlenecks
- How to solve the issue of small patient populations through statistical innovation, regulatory flexibility and patient-centricity
- Utilising Real-World Data and natural history studies
- Creating meaningful endpoints that improves patients’ quality of life
What does this mean for R&D of medicines for small populations?
How will the new mechanism of action provisions impact rare tumours and paediatric diseases with unmet needs?